Ipsen Acquires Memo Therapeutics to Advance BK Virus Treatment
Ipsen has agreed to acquire Memo Therapeutics AG in a deal designed to strengthen its rare disease pipeline with potravitug, a Phase II clinical-stage monoclonal antibody for BK…
Read More...
Read More...
